MA34734B1 - Nouvelle bactérie et extraits de ladite bactérie, et leur utilisation en dermatologie - Google Patents

Nouvelle bactérie et extraits de ladite bactérie, et leur utilisation en dermatologie

Info

Publication number
MA34734B1
MA34734B1 MA36009A MA36009A MA34734B1 MA 34734 B1 MA34734 B1 MA 34734B1 MA 36009 A MA36009 A MA 36009A MA 36009 A MA36009 A MA 36009A MA 34734 B1 MA34734 B1 MA 34734B1
Authority
MA
Morocco
Prior art keywords
extracts
dermatology
bacterium
relates
novel bacteria
Prior art date
Application number
MA36009A
Other languages
English (en)
Inventor
Philippe Lebaron
Muriel Bourrain
Nathalie Castex-Rizzi
Thien Nguyen
Original Assignee
Univ Paris Curie
Centre Nat Rech Scient
Fabre Pierre Dermo Cosmetique
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=44359781&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MA34734(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Univ Paris Curie, Centre Nat Rech Scient, Fabre Pierre Dermo Cosmetique filed Critical Univ Paris Curie
Publication of MA34734B1 publication Critical patent/MA34734B1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
    • C12N1/20—Bacteria; Culture media therefor
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/08—Antiseborrheics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • A61Q19/007—Preparations for dry skin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • A61Q19/10—Washing or bathing preparations
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
    • C12N1/20—Bacteria; Culture media therefor
    • C12N1/205—Bacterial isolates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
    • A61K2800/40—Chemical, physico-chemical or functional or structural properties of particular ingredients
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12R—INDEXING SCHEME ASSOCIATED WITH SUBCLASSES C12C - C12Q, RELATING TO MICROORGANISMS
    • C12R2001/00—Microorganisms ; Processes using microorganisms
    • C12R2001/01—Bacteria or Actinomycetales ; using bacteria or Actinomycetales
    • C12R2001/36—Neisseria

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Microbiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Dermatology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Virology (AREA)
  • Biomedical Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Birds (AREA)
  • Peptides Or Proteins (AREA)
  • Cosmetics (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La présente invention concerne une nouvelle souche bactérienne isolée à partir de l'eau souterraine. L'invention concerne également des extraits bactériens et l'utilisation de ceux-ci dans le contexte du traitement d'inflammations. Plus particulièrement, la présente invention concerne de nouvelles compositions d'intérêt dans le traitement et la prévention de troubles inflammatoires, notamment des pathologies dermatologiques.
MA36009A 2010-12-22 2013-06-13 Nouvelle bactérie et extraits de ladite bactérie, et leur utilisation en dermatologie MA34734B1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR1061081A FR2969657B1 (fr) 2010-12-22 2010-12-22 Nouvelle bacterie et extraits de ladite bacterie et leur utilisation en dermatologie
PCT/EP2011/073747 WO2012085182A1 (fr) 2010-12-22 2011-12-22 Nouvelle bactérie et extraits de ladite bactérie, et leur utilisation en dermatologie

Publications (1)

Publication Number Publication Date
MA34734B1 true MA34734B1 (fr) 2013-12-03

Family

ID=44359781

Family Applications (1)

Application Number Title Priority Date Filing Date
MA36009A MA34734B1 (fr) 2010-12-22 2013-06-13 Nouvelle bactérie et extraits de ladite bactérie, et leur utilisation en dermatologie

Country Status (30)

Country Link
US (2) US9084811B2 (fr)
EP (1) EP2655595B1 (fr)
JP (2) JP6117111B2 (fr)
KR (1) KR102043472B1 (fr)
CN (1) CN103403144B (fr)
AR (1) AR084454A1 (fr)
AU (1) AU2011347254B2 (fr)
BR (1) BR112013015998A2 (fr)
CA (1) CA2821653C (fr)
CL (1) CL2013001853A1 (fr)
CO (1) CO6741177A2 (fr)
DK (1) DK2655595T3 (fr)
ES (1) ES2689138T3 (fr)
FR (1) FR2969657B1 (fr)
GE (1) GEP201606589B (fr)
HK (1) HK1187366A1 (fr)
IL (1) IL226943B (fr)
MA (1) MA34734B1 (fr)
MX (1) MX345125B (fr)
MY (1) MY173066A (fr)
NZ (1) NZ612294A (fr)
PL (1) PL2655595T3 (fr)
PT (1) PT2655595T (fr)
RU (1) RU2612790C2 (fr)
SG (1) SG191236A1 (fr)
TN (1) TN2013000249A1 (fr)
TW (1) TW201307551A (fr)
UA (1) UA113399C2 (fr)
WO (1) WO2012085182A1 (fr)
ZA (1) ZA201304355B (fr)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013190106A1 (fr) * 2012-06-21 2013-12-27 Pierre Fabre Medicament Utilisation d'une bactérie vivante pour le traitement de troubles intestinaux inflammatoires
EP3049418A1 (fr) 2013-09-25 2016-08-03 Vertex Pharmaceuticals Incorporated Imidazopyridazines utiles en tant qu'inhibiteurs de la voie de signalisation par-2
FR3065009B1 (fr) * 2017-04-06 2020-11-27 Fabre Pierre Dermo Cosmetique Secretome bacterien pour son utilisation dans le traitement des lesions cutanees
FR3081705B1 (fr) 2018-06-01 2020-12-04 Fabre Pierre Dermo Cosmetique Extrait et composition dermatologique le comprenant pour le traitement des peaux sensibles
FR3114024B1 (fr) 2020-09-11 2022-09-09 Fabre Pierre Dermo Cosmetique Nouvelle émulsion mimant la peau

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0450015B1 (fr) * 1989-10-06 1995-06-07 János SZABO Composition pharmaceutique destinee au traitement des maladies de la peau, notamment la dermatite pyogenique ou atopique, et procede de preparation
CH680045A5 (fr) * 1990-02-16 1992-06-15 Om Lab Sa
WO1997009032A1 (fr) * 1995-09-07 1997-03-13 L'oreal Utilisation d'un extrait d'une bacterie filamenteuse non photosynthetique et composition le contenant
EP1495039A4 (fr) * 2002-03-20 2006-07-26 Univ Emory Mutants de neisseria, lipooligosaccharides et compositions immunogenes
GB0321615D0 (en) * 2003-09-15 2003-10-15 Glaxo Group Ltd Improvements in vaccination
WO2005030133A2 (fr) * 2003-09-22 2005-04-07 Yale University Traitement utilisant des agonistes des recepteurs toll
US7244607B2 (en) * 2003-10-01 2007-07-17 The United States Of America, As Represented By The Secretary Of Agriculture Chromobacterium subtsugae sp. nov. for control of insect pests
AU2008222865B2 (en) * 2007-03-05 2013-01-31 Om Pharma Bacterial extract for respiratory disorders and proces for its preparation
FR2918883B1 (fr) * 2007-07-17 2010-01-15 Oreal Utilisation d'un extrait bacterien cultive sur une eau thermale pour le traitement des peaux seches
FR2918884B1 (fr) * 2007-07-17 2010-01-15 Oreal Utilisation d'extraits bacteriens cultives sur eau thermale comme agent anti-rougeur
FR2918885B1 (fr) * 2007-07-17 2009-08-28 Oreal Utilisation d'extrait de bacterie cultivee sur eau thermale pour diminuer les poches et/ou les cernes perioculaires
EP2274320A1 (fr) * 2008-04-25 2011-01-19 ID Biomedical Corporation of Quebec Procédés de préparation de compositions immunogènes
EP2278994A4 (fr) 2008-04-25 2012-01-18 Inst Systems Biology Vaccins à polypeptides de flagelline
SI22889A (sl) 2008-10-28 2010-04-30 Kemijski inštitut Himerni flagelini za cepiva
WO2010135704A2 (fr) 2009-05-22 2010-11-25 Institute For Systems Biology Protéines bactériennes associées à des sécrétions pour stimuler nlrc4
KR101762610B1 (ko) * 2010-11-05 2017-08-04 삼성전자주식회사 이동 통신 시스템에서 역방향 스케줄링 및 그를 위한 정보 전송 방법 및 장치

Also Published As

Publication number Publication date
KR20140030109A (ko) 2014-03-11
JP6117111B2 (ja) 2017-04-19
MX2013007217A (es) 2014-01-08
CA2821653A1 (fr) 2012-06-28
RU2013132895A (ru) 2015-01-27
EP2655595A1 (fr) 2013-10-30
AU2011347254B2 (en) 2016-07-14
DK2655595T3 (en) 2018-10-08
NZ612294A (en) 2015-05-29
CN103403144A (zh) 2013-11-20
US20130316033A1 (en) 2013-11-28
JP2014503211A (ja) 2014-02-13
CA2821653C (fr) 2020-03-10
HK1187366A1 (zh) 2014-04-04
UA113399C2 (xx) 2017-01-25
CN103403144B (zh) 2015-11-25
CL2013001853A1 (es) 2014-03-28
EP2655595B1 (fr) 2018-07-04
AR084454A1 (es) 2013-05-15
BR112013015998A2 (pt) 2017-04-11
ZA201304355B (en) 2014-11-26
ES2689138T3 (es) 2018-11-08
RU2612790C2 (ru) 2017-03-13
SG191236A1 (en) 2013-07-31
TW201307551A (zh) 2013-02-16
FR2969657B1 (fr) 2014-02-07
MY173066A (en) 2019-12-23
IL226943B (en) 2019-02-28
US20150231187A1 (en) 2015-08-20
WO2012085182A1 (fr) 2012-06-28
JP2017099393A (ja) 2017-06-08
GEP201606589B (en) 2017-01-10
MX345125B (es) 2017-01-17
FR2969657A1 (fr) 2012-06-29
AU2011347254A1 (en) 2013-07-11
TN2013000249A1 (en) 2014-11-10
US9662357B2 (en) 2017-05-30
KR102043472B1 (ko) 2019-11-11
US9084811B2 (en) 2015-07-21
PT2655595T (pt) 2018-11-02
CO6741177A2 (es) 2013-08-30
PL2655595T3 (pl) 2019-07-31

Similar Documents

Publication Publication Date Title
MA34734B1 (fr) Nouvelle bactérie et extraits de ladite bactérie, et leur utilisation en dermatologie
NO20084024L (no) Imidazolbaserte forbindelser, preparater omfattende slike, og anvendelse av slike
TN2010000068A1 (en) Anticorps anti-cd37
WO2011094545A3 (fr) Compositions et procédés pour améliorer l'activité des protéasomes
MA47440B1 (fr) Sulfonylurées, composés apparentés, et leur utilisation
MA31767B1 (fr) Composes organiques et leurs utilisations
MA44674A (fr) Inhibiteurs de bromodomaine
MA35365B1 (fr) Pyrimidines annelées substituées et leur utilisation
EA201270824A1 (ru) Соединения для уменьшения продукции бета-амилоида
MY146590A (en) Probiotic bifidobacterium strains
EA201190217A1 (ru) Замещенные 2-ацетамидо-5-арил-1,2,4-триазолоны и их применение
MA31667B1 (fr) Induction dun phenotype tolerogene dans des cellules dendritiques matures
EA201300471A1 (ru) Замещенные 6-аминоникотинамиды в качестве модуляторов kcnq2/3
WO2011022357A3 (fr) Enzymes de clivage de snare à action rapide
RS53617B1 (en) NEW UNITS USEFUL FOR TREATMENT OF DEGENERATIVE AND INFLAMMATORY DISEASES
MX2010000266A (es) Un método para disminuir los síntomas del consumo de alcohol.
DK1397105T3 (da) Præparat til inhibering af angiogenese
FR2959128B1 (fr) Utilisation cosmetique d'un lysat de bifidobacterium species pour le traitement des odeurs corporelles
EP4265267A3 (fr) Peptides permettant de moduler l'activité des lymphocytes t et leurs utilisations
MA35895B1 (fr) Inhibiteurs d'iap
MA35457B1 (fr) Nouvelles formulations de pyriméthanil et leur utilisations dans le traitement des cultures
MA32158B1 (fr) Thiazolyldihydroindazoles
MX350145B (es) Extracto proteolitico a partir de bromelaina para el tratamiento de trastornos del tejido conectivo.
MX345124B (es) Bacteria novedosa y estractos de la bacteria y el uso de la misma en terapia.
FR2917089B1 (fr) Nouveaux 4-heteroaryl-imidazole-2-thiones comme inhibiteurs de la tyrosinase, leur procede de preparation et leur utilisation en medecine humaine ainsi qu'en cosmetique.